Researchers from Penn Dental Medicine at the University of Pennsylvania have developed an experimental plant-based antiviral chewing gum that may help reduce the viral load present in saliva, potentially lowering the risk of virus transmission through oral secretions.
The innovation is based on a naturally occurring protein called FRIL (Flt3 Receptor Interacting Lectin), extracted from lablab beans (Lablab purpureus). Laboratory studies show that FRIL can bind to viral surface proteins, preventing viruses from attaching to and entering human cells.
How the Antiviral Gum Works
Unlike traditional antiviral drugs that act systemically, this chewing gum is designed to work locally in the oral cavity, where many respiratory viruses are known to replicate and spread.
Key features of the technology include:
- Sustained release of antiviral proteins during chewing
- Ability to neutralize virus particles in saliva
- Non-invasive delivery method, increasing ease of use
- Stability of antiviral proteins during storage and consumption
In controlled laboratory experiments, the gum demonstrated a greater than 95% reduction in detectable viral load of SARS-CoV-2 and influenza A in saliva samples.
Potential Applications and Use Cases
While still under clinical evaluation, researchers suggest the chewing gum could eventually serve as:
- A supplementary infection-control measure in high-risk environments
- A supportive tool alongside vaccines and public health interventions
- A preventive aid for healthcare workers, caregivers, and teachers
- A temporary mitigation method during outbreaks or pandemics
Scientists stress that the gum is not a cure, nor a replacement for vaccination, masking, or medical treatment.
Regulatory Status and Current Limitations
The antiviral chewing gum remains in the research and pre-clinical phase. Before public availability, it must undergo:
- Human clinical trials
- Safety and dosage validation
- Regulatory review by health authorities
Experts caution against overstating its effectiveness until large-scale clinical evidence becomes available.
Why This Innovation Matters
This research highlights a growing trend in biotechnology-driven preventive healthcare, where natural compounds and biomaterials are engineered into practical, everyday products. It also demonstrates how simple delivery mechanisms, such as chewing gum, can be reimagined to address complex public health challenges.
As global health systems seek scalable, low-cost tools to complement traditional interventions, such innovations could play a meaningful role in future pandemic preparedness strategies.
Verified & Trustworthy Sources
- Penn Dental Medicine – University of Pennsylvania
https://penntoday.upenn.edu/news/penn-dental-antiviral-chewing-gum-reduce-influenza-and-herpes-simplex-virus-transmission
Editorial Note
This article is published for informational and educational purposes only and does not constitute medical advice.
